Finoriq research workspace
Jazz Pharmaceuticals plc (JAZZ) SEC Filings & Filing Highlights
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the. Review JAZZ SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
- Company
- Jazz Pharmaceuticals plc (JAZZ)
- Ticker
- JAZZ
- Market Cap
- $15.4B
- Latest Price
- $244.78
- Industry
- Biotech & Pharma
Jazz Pharmaceuticals plc (JAZZ) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Jazz Pharmaceuticals plc (JAZZ).
| Event | Form | Date |
|---|---|---|
| On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceut...On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meetin... | 8-K5.02 | 2026-05-29 |
| Jazz Pharmaceuticals plc: Earnings or resultsOn May 5, 2026, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the... | 8-K2.02 | 2026-05-05 |
| Jazz Pharmaceuticals plc: Earnings or resultsOn February 24, 2026, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results fo... | 8-K2.02 | 2026-02-24 |
| January 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Dis...January 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Disease Renee Gala, President & CEO | 8-K2.02 | 2026-01-12 |
| Company plans to submit a supplemental BLA for this indication in first half of 2026Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regime... | 8-K8.01 | 2025-11-17 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.